QJM : monthly journal of the Association of Physicians · 2012
Does an interferon-gamma release assay change practice in possible latent tuberculosis?
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tiernan J F, Gilhooley S, Jones M E, Chalmers J D, McSparron C, Laurenson I F, Hill A T
Аннотация
BACKGROUND AND AIMS: Suspected latent tuberculosis infection (LTBI) is a common reason for referral to TB clinics. Interferon-gamma release assays (IGRAs) are more specific than tuberculin skin tests (TSTs) for diagnosing LTBI. The aim of this study is to determine if IGRA changes practice in the management of cases referred to a TB clinic for possible LTBI.
DESIGN AND METHODS: A prospective study was performed over 29 months. All adult patients who had TST, CXR & IGRA were included. The original decision regarding TB chemoprophylaxis was made by TB team consensus, based on clinical history and TST. Cases were then analysed with the addition of IGRA to determine if this had altered management. An independent physician subsequently reviewed the cases.
RESULTS: Of 204 patients studied, 68 were immunocompromised. 120 patients had positive TSTs. Of these, 36 (30%) had a positive QFT and 84 (70%) had a negative QFT. Practice changed in 78 (65%) cases with positive TST, all avoiding TB chemoprophylaxis due to QFT. Of the immunocompromised patients, 17 (25%) underwent change of practice. No cases of active TB have developed.
CONCLUSION: This study demonstrates a significant change of clinical practice due to IGRA use. Our findings support the NICE 2011 recommendations.
DESIGN AND METHODS: A prospective study was performed over 29 months. All adult patients who had TST, CXR & IGRA were included. The original decision regarding TB chemoprophylaxis was made by TB team consensus, based on clinical history and TST. Cases were then analysed with the addition of IGRA to determine if this had altered management. An independent physician subsequently reviewed the cases.
RESULTS: Of 204 patients studied, 68 were immunocompromised. 120 patients had positive TSTs. Of these, 36 (30%) had a positive QFT and 84 (70%) had a negative QFT. Practice changed in 78 (65%) cases with positive TST, all avoiding TB chemoprophylaxis due to QFT. Of the immunocompromised patients, 17 (25%) underwent change of practice. No cases of active TB have developed.
CONCLUSION: This study demonstrates a significant change of clinical practice due to IGRA use. Our findings support the NICE 2011 recommendations.
Предметные рубрики MeSH
AdultAntitubercular AgentsDisease ProgressionDrug Therapy, CombinationFemaleHumansInterferon-gamma Release TestsIsoniazidLatent TuberculosisMaleMycobacterium tuberculosisPractice Guidelines as TopicPredictive Value of TestsProspective StudiesReferral and ConsultationReproducibility of ResultsRifampinRisk AssessmentScotlandSensitivity and SpecificityTuberculin Test